Summary
Johnson & Johnson (JNJ) announced the completion of its acquisition of Micrus Endovascular Corporation on September 27, 2010. This strategic move expands JNJ's presence in the medical device sector, specifically targeting the rapidly growing neurovascular market for stroke treatment. The acquisition of Micrus, a developer and manufacturer of minimally invasive devices for both hemorrhagic and ischemic strokes, positions Johnson & Johnson to leverage its global reach and resources to further advance and commercialize these innovative technologies.
Key Highlights
- 1Johnson & Johnson has completed the acquisition of Micrus Endovascular Corporation.
- 2The acquisition focuses on the neurovascular market, specifically stroke treatment devices.
- 3Micrus Endovascular Corporation specializes in minimally invasive devices for hemorrhagic and ischemic strokes.
- 4This acquisition represents a strategic expansion for JNJ in the medical device segment.
- 5The deal was announced via a press release dated September 27, 2010.
- 6The filing is an 8-K report, indicating a significant material event.
Frequently Asked Questions
The main event reported is the completion of Johnson & Johnson's acquisition of Micrus Endovascular Corporation.
Micrus Endovascular Corporation develops and manufactures minimally invasive devices for the treatment of hemorrhagic and ischemic strokes.
This acquisition strengthens Johnson & Johnson's position in the neurovascular market, a key area within the medical device industry, by adding Micrus's specialized stroke treatment technologies.
The acquisition was completed on September 27, 2010, as announced in the press release dated the same day.